7-9 September, Amsterdam
![]() |
![]() |
![]() |
![]() |
P-01 | Multimodal and spatial analysis of tumour-immune microenvironment in steatosis-driven hepatocellular carcinoma | Aldo Prawira | ![]() |
![]() |
|||
P-02 | Inhibition of PARP-1 in KRAS-mutated intrahepatic cholangiocarcinoma exerts positive effects and is mediated by CHK1 kinase | Darko Castven | ![]() |
![]() |
|||
P-03 | Hypoxia promotes adenosine efflux to establish the immunosuppressive microenvironment in liver cancer | Carmen Wong | ![]() |
![]() |
|||
P-04 | Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma | Binghua Li | ![]() |
![]() |
|||
P-05 | Integrated genomic analysis refines molecular classifications of hepatocellular carcinoma based on LICA-FR cohort of 529 samples | Long Pan | ![]() |
![]() |
|||
P-06 | The senescent secretome drives the re-emergence of the fetal receptor PLVAP on human hepatic endothelium to promote monocyte transmigration. | Shishir Shetty | ![]() |
![]() |
|||
P-07 | Inactivation of histone chaperone complex CAF-1 elicits intrinsic anti-cancer immunity through activating the cytosolic DNA and dsRNA sensing pathways in hepatocellular carcinoma | Chun-Ming Wong | ![]() |
![]() |
|||
P-08 | Outcome of Targeting ATR in High Replication Stress murine HCC | JING FANG | ![]() |
![]() |
|||
P-09 | Genetic and pathologic features of papillary neoplasms of human biliary system of intrahepatic and extrahepatic bile ducts and gallbladder | Young Nyun Park | ![]() |
![]() |
|||
P-13 | Financial and Psychological Burden of HCC Surveillance in Patients with Cirrhosis | Amit Singal | ![]() |
![]() |
|||
P-14 | Achievement of Cancer and Drug-free Status by Atezolizumab Plus Bevacizumab Followed by Curative Conversion in Patients with TACE-Unsuitable, Intermediate-stage HCC: A Multicenter Proof-of-Concept Study | Masatoshi Kudo | ![]() |
![]() |
|||
P-15 | VETC (vessel that encapsulate tumor cluster) EVALUATED IN LIVER BIOPSY PREDICTS ANTI-ANGIOGENIC BENEFIT IN ADVANCED HCC | Luca Di Tommaso | ![]() |
![]() |
|||
P-17 | Association with body mass index and risk of hepatocellular carcinoma according to liver disorder status | HEEJAE JUNG | ![]() |
![]() |
|||
P-19 | Drug-eluting beads vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: A Randomized Clinical Trial | Jun-Hui Sun | ![]() |
![]() |
|||
P-20 | Prospective study of surveillance non-contrast abbreviated MRI for hepatocellular cancer in patients with suboptimal hepatic visualisation on ultrasound | Mathew Vithayathil | ![]() |
![]() |
|||
P-22 | Genomic characteristics of hepatocellular carcinoma patients with response to sorafenib | Sun Young Yim | ![]() |
![]() |
|||
P-24 | Cytokine levels and circulating DNA in plasma could be used as serological biomarkers of response to immunotherapy in hepatocellular carcinoma | Beatriz Mínguez | ![]() |
![]() |
|||
P-25 | Preliminary Safety Results of a Phase 1/2 Open-label Study on an Anti-GPC3 T-cell Engager, SAR444200, in Patients with Advanced Solid Tumors | Asma Kefsi | ![]() |
![]() |
|||
P-27 | Constructing and Experimentally Validating a Disulfidptosis-related Ferroptosis Gene-driven Machine Learning Prognostic Risk Model for Liver Cancer | Cong Zhang | ![]() |
![]() |
|||
P-28 | Serine utilization and generation of different lipid species influence the response of hepatocellular carcinoma to lipid depletion | Bichitra Paul | ![]() |
![]() |
|||
P-31 | B-CATENIN PATHWAY MUTATIONS PREDICT FAVORABLE OUTCOMES AFTER TRANSARTERIAL CHEMOEMBOLIZATION IN UNRESECTABLE HEPATOCELLULAR CARCINOMA | Kelley Weinfurtner | ![]() |
![]() |
|||
P-32 | Lipid-Associated TREM2 Macrophages Mediates Immunosuppressive Microenvironment in Liver Metastasis of Colorectal Cancer | Pengxiang Wang | ![]() |
![]() |
|||
P-33 | Identification of novel phosphoproteomic biomarkers in patients with advanced hepatocellular carcinoma (HCC) | Federico Pedicona | ![]() |
![]() |
|||
P-34 | Evaluation of Src family of tyrosine kinases and their potential as molecular targets in overcoming liver cancer heterogeneity | Loraine Kay Cabral | ![]() |
![]() |
|||
P-35 | Inflammation induced IgA upregulates PD-L1 in cancer associated fibroblasts of HCC and attenuates CD8 T cell function | Sung Woo Cho | ![]() |
![]() |
|||
P-36 | Nanosecond pulsed electric field ablation of sequential endothelial progenitor cell-directed endothelial inhibitor/suicide fusion gene for the treatment of hepatocellular carcinoma | Li Jing | ![]() |
![]() |
|||
P-37 | Combinations of fostrox (MIV-818), a novel nucleotide prodrug, with lenvatinib or sorafenib shows increased efficacy in nonclinical hepatocellular carcinoma (HCC) models in vivo | Fredrik Oberg | ![]() |
![]() |
|||
P-38 | Impact of exosomal miR-4669 on tumor cell behavior and immunosuppressive tumor microenvironment in hepatocellular carcinoma | Toshiaki Nakano | ![]() |
![]() |
|||
P-39 | New insight in HCC immuno-vascular microenvironment: interplay between tumoral macrophages and VETC | Camilla De Carlo | ![]() |
![]() |
|||
P-40 | Functional dissection of immune infiltrate reveals that HCC enriched VETC vascular phenotype is characterized by the presence of exhausted T cells. | Barbara Durante | ![]() |
![]() |
|||
P-41 | Poor sorafenib response in hepatocellular carcinoma is mediated by hypoxia-associated 14-3-3 scaffolding proteins with observed alterations in immune micromilieu | Jovana Castven | ![]() |
![]() |
|||
P-42 | Synergistic antitumor activity of lenvatinib and lipophilic statins in hepatocellular carcinoma | Hyeyeon Hong | ![]() |
![]() |
|||
P-44 | GDF11 reduces aggressive behavior provided by tumor-associated macrophages on HCC-derived cells. | Oscar Alejandro Escobedo Calvario | ![]() |
![]() |
|||
P-45 | Effect of Zinc Acexamate treatment in hepatocellular carcinoma in vitro and in vivo models | Beatriz Mínguez | ![]() |
![]() |
|||
P-46 | Identification of the epidrivers facilitating hepatocellular carcinoma recurrence | Hyun Goo Woo | ![]() |
![]() |
|||
P-47 | Gene regulatory network analysis on snRNAseq revealed key regulators for hepatocellular carcinoma progression | Su Jong Yu | ![]() |
![]() |
|||
P-48 | Lenvatinib induced cell death of hepatocellular carcinoma by increasing HIF-a degradation under hypoxic condition | Sung Won Chung | ![]() |
![]() |
|||
P-50 | CD73 expression on liver endothelium is promoted by tumour associated stimuli and could contribute to the immunosuppressive microenvironment in hepatocellular carcinoma | Rosemary Faulkes | ![]() |
![]() |
|||
P-51 | Fructose promotes chemoresistance through the induction of a metabolic rewiring in liver cancer cells and a KHK-A/p27 non-canonical pathway. | Lisette Chávez Rodríguez | ![]() |
![]() |
|||
P-52 | LI-RADS classification of proliferative hepatocellular carcinomas and its implication on prognosis | Subin Heo | ![]() |
![]() |
|||
P-54 | The Outcomes of Patients with Hepatocellular Carcinoma and with Child-Turcotte-Pugh Class B | Chia Chu Fu | ![]() |
![]() |
|||
P-55 | Prediction of Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients following HBsAg seroclearance | Jonggi Choi | ![]() |
![]() |
|||
P-56 | Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCC | Federico Piñero | ![]() |
![]() |
|||
P-58 | Tumor response-based nomogram for ion of patients with hepatocellular carcinoma benefitting from drug-eluting bead transarterial chemoembolization | Cong Zhang | ![]() |
![]() |
|||
P-59 | Effect of chemotherapeutic agents on acute kidney injury in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: doxorubicin versus cisplatin | Won Sohn | ![]() |
![]() |
|||
P-60 | Treatment outcomes in patients with advanced fibrolamellar hepatocellular carcinoma: analysis of clinical characteristics and radiomics phenotypes | Leonardo da Fonseca | ![]() |
![]() |
|||
P-63 | Implication of patients experience in the liver cancer multidisciplinary approach | Gemma Iserte | ![]() |
![]() |
|||
P-65 | Sarcopenia affects the therapeutic efficacy of immunotherapy for advanced Hepatocellular carcinoma. | Takuya Kuwashiro | ![]() |
![]() |
|||
P-68 | Consistent efficacy of Hepatic Artery Infusion Chemotherapy irrespective of PD-L1 positivity in unresectable hepatocellular carcinoma | Ji Hoon Kim | ![]() |
![]() |
|||
P-69 | Differences in Outcomes Between Screen-Detected and Non-Screen Detected Hepatocellular Carcinoma | Darine Daher | ![]() |
![]() |
|||
P-71 | Correlates and Outcomes of CT or MRI-based Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis | Darine Daher | ![]() |
![]() |
|||
P-72 | Clinical Performance of GAAD and GALAD Algorithmic Scores for Hepatocellular Carcinoma (HCC) surveillance in Patients with Chronic Hepatitis | Ming-Lung Yu | ![]() |
![]() |
|||
P-74 | Discrepancy between the real clinical status of patients with HCC and expectations from HCC surveillance: a single center study | Jiwoong Jang | ![]() |
![]() |
|||
P-75 | Peripheral immune markers can detect hepatocellular carcinoma in blood in a Latin American cohort | Andre Boonstra | ![]() |
![]() |
|||
P-76 | Evaluation of the Accuracy of Imaging Diagnosis for Hepatocellular Carcinoma in Chronic Hepatitis C Patients without Liver Cirrhosis | Jihyun An | ![]() |
![]() |
|||
P-80 | Differentiation of Primary Malignant Vascular Tumors using CT and Gadoxetate-enhanced Liver MRI | So Yeon Kim | ![]() |
![]() |
|||
P-81 | Pan-viral serology uncovers distinct virome patterns among hepatocellular carcinoma and control populations | Whitney Do | ![]() |
![]() |
|||
P-82 | Role of Tumor Markers in Diagnosing Recurrent Hepatocellular Carcinoma after Curative Resection | Jeong Ah Hwang | ![]() |
![]() |
|||
P-83 | Performance of tumor-specific microRNAs as plasma biomarkers of hepatocellular carcinoma in patients with liver cirrhosis | Robin Zenlander | ![]() |
![]() |
|||
P-85 | Five-year on-treatment parameters-based model predicts subsequent hepatocellular carcinoma in entecavir/tenofovir-treated patients | Yeonjung Ha | ![]() |
![]() |
|||
P-86 | Evaluating performance of aMAP score in predicting hepatocellular carcinoma development over a two-year period in cirrhosis patients | Avisnata Das | ![]() |
![]() |
|||
P-89 | Early detection of hepatocellular carcinoma using urinary metabolomic biomarkers in an Australian Aboriginal population. | Paula Binks | ![]() |
![]() |
|||
P-90 | Physician and patient survey of practices and perspectives in the surveillance and diagnosis of hepatocellular carcinoma (HCC) in Asia: unmet needs in the real world | Iain Murdoch | ![]() |
![]() |
|||
P-91 | IMbrave050: Phase 3 study of adjuvant atezolizumab bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | Elyse Viana | ![]() |
![]() |
|||
P-92 | Risk of Gastrointestinal Bleeding in Patients Receiving AtezolizumabBevacizumab Treatment for Hepatocellular Carcinoma | Jonggi Choi | ![]() |
![]() |
|||
P-93 | Real-world (RW) systemic treatment patterns in US patients (pts) with hepatocellular carcinoma (HCC): 20202022 | Rego Team | ![]() |
![]() |
|||
P-94 | Systemic Treatment in Child Pugh B Patients with Hepatocellular Carcinoma | Kevin Mok | ![]() |
![]() |
|||
P-95 | Semaglutide, but not lanifibranor, promotes tumor regression in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH with advanced fibrosis and HCC | Denise Oró | ![]() |
![]() |
|||
P-96 | Metabolic dysfunction associated fatty liver disease and the risk of hepatocellular carcinoma | BYEONGGEUN SONG | ![]() |
![]() |
|||
P-97 | Randomized phase II trial to assess safety and efficacy of regorafenib in patients with advanced hepatocellular carcinoma who were not included in the RESORCE trial: REGAIN trial | Keisuke Koroki | ![]() |
![]() |
|||
P-98 | A Study on the Sequence of Systemic Treatment in Hepatocellular Carcinoma | Kevin Mok | ![]() |
![]() |
|||
P-99 | Macrotrabecular-Massive pattern is associated with aggressive factors, but it is not an independent predictor of tumor recurrence and overall survival in patients with hepatocelular carcinoma treated with liver resection | Ezequiel Mauro | ![]() |
![]() |
|||
P-100 | Validation of Baveno-VII criteria for clinically significant portal hypertension in patients with compensated advanced chronic liver disease | BYEONGGEUN SONG | ![]() |
![]() |
|||
P-101 | The predictive value of liver volume on hepatic decompensation and the long-term effects of stereotactic body radiation therapy on hepatic decompensation | JINHONG JUNG | ![]() |
![]() |
|||
P-102 | A prospective study to evaluate the safety and efficacy of lenvatinib in patients with advanced hepatocellular carcinoma to maximise its potential in current practice | Kazufumi Kobayashi | ![]() |
![]() |
|||
P-104 | Real-time US-CT/MR Fusion Imaging-guided Anatomical Ablation for Small Hepatocellular Carcinomas Using Multiple Applicators: A Preliminary Study | Jae Hyun Kim | ![]() |
![]() |
|||
P-105 | Glypican-3-targeted radiopharmaceutical therapy for hepatocellular carcinoma: Preclinical characterization of a novel peptide radioligand | Fanching Lin | ![]() |
![]() |
|||
P-107 | A Multicenter Propensity Score Matching Analysis of the Clinical Outcome of Atezolizumab/Bevacizumab and Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Comparative study | Hee Sun Cho | ![]() |
![]() |
|||
P-108 | Single arm study to evaluate the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma patients in Japanese real-world practice; focusing on the complement of the REACH-2 study: R-evolution trial | Kazufumi Kobayashi | ![]() |
![]() |
|||
P-109 | Interim analysis of the ACTION trial: Cabozantinib for hepatocellular carcinoma patients who discontinued first line treatment other than sorafenib or due to sorafenib intolerance | Marco Sanduzzi Zamparelli | ![]() |
![]() |
|||
P-110 | Lung-specific response to atezolizumab plus bevacizumab is associated with overall survival in patients with lung metastasis from hepatocellular carcinoma | Ju Hyun Shim | ![]() |
![]() |
|||
P-111 | Clinical Outcomes of Stereotactic Body Radiation Therapy Alone versus Stereotactic Body Radiation Therapy after Incomplete Transarterial Chemoembolization for a Single Small (= 5 cm) Recurrent Hepatocellular Carcinoma | JINHONG JUNG | ![]() |
![]() |
|||
P-112 | Metastasectomy versus stereotactic body radiation therapy for pulmonary oligometastasis from hepatocellular carcinoma: a propensity score-weighted analysis | Sang Min Yoon | ![]() |
![]() |
|||
P-113 | Palliative care in patients with BCLC-D hepatocellular carcinoma not indicated for liver transplantation: results of a survey among Italian hepatologists and palliative care physicians. | Lorenzo Canova | ![]() |
![]() |
|||
P-114 | Portal-hypertension parameters are associated with transplantation free survival and ascites occurrence in patients with hepatocellular carcinoma treated by external radiotherapy | Héloïse Giudicelli | ![]() |
![]() |
|||
P-115 | Significance of autoantibody assay in patients receiving atezolizumab and bevacizumab combination therapy for unresectable hepatocellular carcinoma | Hitomi Takada | ![]() |
![]() |
|||
P-117 | Value based Healthcare: Patient perception of the liver cancer Advanced Practice Nurse care at the Barcelona Clinic Liver Cancer | Neus Llarch | ![]() |
![]() |
|||
P-118 | Salvage Hepatectomy for Recurrent Hepatocellular Carcinoma after Radiofrequency Ablation | Jai Young Cho | ![]() |
![]() |
|||
P-119 | A real-world comparative analysis of atezolizumab plus bevacizumab and transarterial chemoembolization plus radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombosis | Jong Young Choi | ![]() |
![]() |
|||
P-123 | Liver-directed combined radiotherapy for downstaging of over the Milan advanced hepatocellular carcinoma converting to liver transplantation | jinsil seong | ![]() |
![]() |
|||
P-124 | Comparative Analysis of combination therapy (Atezolizumab bevacizumab) and hepatic artery infusion chemotherapy in Unresectable Hepatocellular carcinoma: A multi-center study | Ji Hoon Kim | ![]() |
![]() |
|||
P-126 | The efficacy and safety of Toripalimab combined with Sorafenib for unresectable hepatocellular carcinoma: An open-label, prospective, single-arm phase II study | Xin-Rong Yang | ![]() |
![]() |
|||
P-127 | Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma | Judith Land | ![]() |
![]() |
|||
P-128 | Association of alcohol consumption with liver cancer and all-cause mortality in chronic hepatitis B patients without cirrhosis | Beom Kyung Kim | ![]() |
![]() |
|||
P-129 | FGFR2 Pathway Activation Beyond The Alteration of FGFR Receptor in Intrahepatic Cholangiocarcinoma | Chiara Deiana | ![]() |
![]() |
|||
P-130 | Differential risk of hepatic events during immune checkpoint inhibitor treatment between hepatocellular carcinoma and other malignancies | Yi-Hsiang Huang | ![]() |
![]() |
|||
P-131 | The expression of Aurora kinase A in hepatocarcinogenesis and its role in Programmed DeathLigand 1 regulation | Luca Grisetti | ![]() |
![]() |
|||
P-132 | Weakly supervised primary liver cancer classification from routine tumour biopsy: a proof of concept | Aurélie Beaufrère | ![]() |
![]() |
7-9 September, Amsterdam
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|